dendritic cells (DCs). Overaccumulation of CD8
+ DCs is seen in colonic mucosa in experimental colitis and patients with inflammatory bowel disease (IBD). CD8 + CD11c + cells may be a potential strategy to explore the mechanism of action of drugs in IBD. The immunosuppressant curcumin (Cur) plays a therapeutic role in various immune diseases, including IBD and rheumatoid arthritis. However, it is unclear whether Cur regulates level of CD8 + CD11c + cells to treat IBD. We found that the therapeutic effect of Cur in experimental colitis was closely related to decreased levels of CD8 
INTRODUCTION
As one of integrin family, CD11c is a type Ⅰ trans membrane protein that mediates adherence between leukocytes and endothelial cells, and participates in exudation and phagocytosis of leukocytes. It is suggested that CD11c induces tissue injury and the inflammatory response [1] . Importantly, CD11c is a specific marker in dendritic cells (DCs) and is highly expressed in CD8 + and CD8 DCs [2] . As professional antigenpresenting cells, DC pre cursors capture antigens and promote Tcell migration to regions of the draining lymph nodes where they can mature into functional DCs and present antigens to initiate Tcellmediated immune responses [3] .
Increasingly, it has been reported that DCs are critical to maintaining intestinal immunity and mucosal immune tolerance to resist the pathogenicity of com mensal microorganisms, which is one of the pivotal inflammatory etiologies of induced inflammatory bowel diseases (IBD) [4] . High expression of costimulatory molecules and major histocompatibility complex (MHC) Ⅱ of DCs, which is a known marker of DC maturation, and a "danger signal" of induced inflammatory mucosal damage in the gut, occurs in the colonic mucosa of animal models of colitis [5, 6] . Moreover, DCs can develop from both myeloid and lymphoid progenitors. In mice, CD8 + DCs have been designated as lymphoid DCs, and
CD8
DCs as myeloid DCs [7] . More importantly, CD8 + DCs predominantly stimulate T helper (Th)1inducing cytokines such as interleukin (IL)12p70 and IL12p40, which can lead to Th1 differentiation [8] , and have been reported to play a key role in controlling viral infection [3, 9, 10] . Overaccumulation of CD8 + DCs induces inflammatory injury in the colonic mucosa when they migrate into Peyer's patches (PPs) in experimental colitis and IBD patients [11, 12] . Thus, CD8 + DCs may be a potential therapeutic target to explore the mechanisms of clinical treatment of IBD. Many studies have indicated that CD11c expressed in DCs can promote maturation and activation of DCs; present antigen for CD4 + or CD8 + T cells; accelerate Tcell activation and proliferation; and produce various cytokines [1315] . CD11c + DCs are depleted by diphtheria toxin during treatment of experimental colitis, induced indirectly by CD4 + CD62L + T cells, with oligodeoxynucleotides containing unmethylated cytosineguanosine [16] . These results suggest that CD11c + DCs play an important role in the pathogenetic process of IBD. Curcumin (Cur) is the major constituent of turmeric powder that is extracted from the rhizomes of Curcuma longa L. Cur has a long history of effectively treating chronic colitis by blocking nuclear factorκB signaling in human IBD and experimental colitis, including trinitrobenzene sulfonic acid (TNBS)induced and dextran sulfate sodium (DSS) induced experimental colitis [1719] . Multifunctional
Cur has exhibited antioxidant, antiinflammatory, antimutagenic, and anticarcinogenic activities, as well as antiplatelet, hypoglycemic, cholesterol lowering, antibacterial, woundhealing and antifungal effects [17, 2022] . In addition, Shirley et al [23] , have
shown that Cur prevents DCs from responding to immunostimulants and DCmediated induction of CD4 + Tcell proliferation by blocking maturation marker expression, cytokine and chemokine expression, and reducing migration and endocytosis. Shirley et al [23] also concluded that Cur might play a therapeutic role as an immunosuppressant in the treatment of various immune diseases including IBD and rheumatoid arthritis. In our previous study, we found that Cur repaired colonic structure, decreased colonic weight and histological injury score, and recovered colonic length, indicating that Cur restored damaged colonic mucosa in mice with TNBSinduced colitis [24] . However, it is unclear whether Cur can regulate the expression levels of CD8
+

CD11c
+ cells to treat IBD.
In the present study, we investigated the effects of Cur on CD8 
MATERIALS AND METHODS
Mice
Nine to twelveweekold male C57BL/6 mice (2024 g) were purchased from the Animal Center of Peking University Health Science Center (Animal Certificate No.: SCXK 20120001). Mice were housed in a special room with a humidity of 50% ± 5% and an equal 12h light/dark cycle at 20 ± 2 ℃ throughout the experimental period. Animals were allowed free access to a commercial diet and clean water ad libitum. All animals were allowed to acclimatize for 4 d before the start of the experiment. The experimental protocols (JZ2015016) were approved by the Biomedical Ethics Committee Experimental Animal Ethics Branch of Jiangxi University of Traditional Chinese Medicine.
Induction of experimental colitis
Colitis was induced according to the procedure des cribed previously by Huang et al [25] , Sałaga et al [26] , Fina et al [27] and Bai et al [28] . Mice were fasted for 12 h. Each mouse was anesthetized with pentobarbital sodium (40 mg/kg), following which, 100 mg/kg TNBS (Sigma Aldrich, St. Louis, MO, United States; 100 g/L dissolved in 0.3 mL 50% ethanol) was instilled via a rubber catheter that was inserted approximately 4 cm into the colon via the anus. The rubber catheter was modified with numerous holes positioned over the final 4 cm of its length. The instillation procedure required only a few seconds, following which the mice were maintained in a headdown position for 5 min to prevent solution leakage. Mice in the Normal group received 50% ethanol of the same volume that was delivered using the same technique as described above.
Treatment protocols
To explore the effect of Cur (purity ≥ 95% by HPLC; Gangrun Biotechnology, Nanjing, China) on CD8 
Assessment of severity of colitis: disease activity index
Disease activity index (DAI) was analyzed according to the previous study [29, 30] , which was the combined score of weight loss, stool consistency, and bleeding. The criteria for DAI scores are described in Table 1 . The changes in growth rate, stool consistency, and gross bleeding or occult blood in the feces were scored daily from 0 to 4 for each animal after TNBS treatment.
Evaluation of colonic damage
On day 8, all mice were killed after being anes thetized with pentobarbital sodium (40 mg/kg) by intraperitoneal injection. The colon was removed rapidly and its length was measured, opened longitudinally, rinsed with phosphatebuffered saline (PBS), assessed immediately for weight, and the weight index of the colon was calculated (colonic 
ELISA
The levels of IL10, IFNγ and TGFβ1 in spleen and colonic mucosa supernatants were measured using ELISA (eBioscience).
Statistical analysis
Data were expressed as mean ± SEM. The statistical significance was evaluated by analysis of variance followed by Tukey's test for multiple comparisons using GraphPad Prism version 5.0 (La Jolla, CA, United States). Nonparametric data were analyzed with the MannWhitney U test. P < 0.05 was considered statistically significant.
RESULTS
Cur attenuated TNBS-induced colitis
The body weight of mice and the disease activity index of experimental colitis in the TNBS group were significantly decreased compared with the Normal, TNBS + Cur and TNBS + Mes groups ( Figure 1B and C). Colonic weight and the weight index of the colon from the TNBS groups were higher than those in the Normal group, but lower than in the TNBS + Cur and TNBS + Mes groups ( Figure 1D and E). However, the colonic length in the colitis mice was shorter in the TNBS group compared with the Normal, TNBS + Cur, and TNBS + Mes groups ( Figure 1A and G). Histological evaluation of colonic sections from untreated mice with colitis showed that TNBSinduced colitis was characterized by a loss of mucosal architecture, thickening of the colon wall, cryptic abscesses, ulcer formation, and extensive inflammatory cell infiltration in the colonic mucosa ( Figure 1F ). Treatment with Cur and Mes inhibited these pathological symptoms and and kept histoprogressive restoration, reduced inflammatory cell infiltration in the mucosa and submucosa, and maintained the integrity of colonic mucosa ( Figure 1F ). We observed visually ulceration, hyperemia and edema in the colonic mucosa in colitis mice without treatment, which were ameliorated in mice treated with Cur and Mes ( Figure 1A ). Moreover, the histological scores in the colon of mice from the Normal, TNBS + Cur, and TNBS + Mes groups were significantly lower than those in untreated mice with colitis ( Figure 1F and H). All results demonstrated that Cur effectively treated experimental colitis.
Cur inhibited levels of CD8 + CD11c + cells in spleen and PPs in colitis mice
We analyzed the numbers of CD8 weight/body weight × 100%). Segments of the colon were fixed in 4% paraformaldehyde for at least 7 d. Subsequently, colon tissues were dehydrated, embedded in paraffin, sectioned at 5 μm and mounted onto slides. These sections were stained with hematoxylin and eosin. A histological damage score was determined according to the criteria of Nicole and Schmidt et al [31] . The histological score included inflammatory cell infiltration and tissue damage. Scores for infiltration were as follows: 0: no infiltration; 1: increased number of inflammatory cells in the lamina propria; 2: inflammatory cells extending into the submucosa; and 3: transmural inflammatory cell infiltration. The scores of tissue damage were as follows: 0: no mucosal damage; 1: discrete epithelial lesions; 2: erosions or focal ulcerations; and 3: severe mucosal damage with extensive ulceration extending into the bowel wall.
Isolation of lymphocyte from spleen and PPs
PPs were separated and collected from the small intestine to the terminal rectum. To prepare singlecell suspensions, spleens or PPs were minced and digested in 2 mg/mL collagenase D (Roche Diagnostics, Basel Switzerland) in 1% fetal calf serum (FCS)/RPMI 1640 for 15 min at 37 ℃. Next, 10 mM EDTA was added for the last 5 min, and the cell suspensions were then pipetted up and down several times and filtered through a fine-mesh sieve. The cell suspensions were centrifuged at 380 × g at 4 ℃ for 5 min and suspended at a density of 10 
Assay of CD8 + CD11c + cells by flow cytometry
After removal of RBC, splenic and PPs cells were labeled with V450antimouse CD8a + antibody (0.125 μg/100 μL; BD Biosciences, San Jose, CA, United States) and APC/Cy7 antimouse CD11c (eBioscience, San Diego, CA, United States), respectively, at 37 ℃ in the dark. Cells were centrifuged at 380 × g at 4 ℃ for 5 min, and fixed in 1% paraformaldehyde/PBS. In addition, fluorescenceactivated cell sorting analysis was performed on a FACSCalibur flow cytometer (BD Biosciences). 
Measurement of co-stimulatory molecules of
Cur increased IL-10, IFN-γ and TGF-β 1 secretion in spleen and colonic mucosa in colitis mice
To understand the effects of activated CD8 + CD11c + cells in the development of murine colitis, the secretion of IL10, IFNγ and TGFβ1 was determined ( Figure  3 ). There was significantly increased expression of TGFβ1 in the colonic mucosa of untreated colitis mice ( Figure 3B ). In addition, the secretion of TGFβ1 in the colonic mucosa in the TNBS + Cur and TNBS + Mes groups was lower than that in the TNBS group. However, expression of TGFβ1 in the spleen of mice treated with Cur and Mes was higher than that in the TNBS group compared with the Normal group, levels of IFNγ ( Figure 3B and E) and IL10 ( Figure 3C and F) in the spleen and colonic mucosa in untreated colitis mice were decreased 7 d after TNBSinduced colitis. In the colonic mucosa and spleen, the expression of both IL10 and IFNγ was increased in colitis mice treated with Cur and Mes as compared with untreated colitis mice. 
DISCUSSION
In the present study, the DAI, colonic weight, weight index of the colon, and histological score of colonic of experimental colitis were significantly decreased after Cur treatment, while the body weight and colonic length were recovered. The results indicate that Cur can effectively treat experimental colitis. The numbers of CD8 + CD11C + cells in the spleen and PPs were decreased, which showed that the therapeutic effect of Cur on colitis was related to the number of CD8 + CD11C + cells.
As a positive regulatory factor, CD11c, which is an adhesion molecule in the CD11/CD18 family, can promote DC activation and maturity by elevating expression of costimulatory molecules [32, 33] . Activated CD11c + DCs secrete a large number of inflammatory factors (including IL1β, IL6, IL12 and IL20) and promote CD4 + T cells transformation into Th 1 cells, inducing inflammatory injury [34] . In the present study, the total number of CD8 + CD11c
+ cells in the spleen and PPs increased in colitis mice, which decreased with Cur treatment. Our previous study indicated that Cur alleviated inflammatory injury in the colonic mucosa of colitis mice, using the same model as in the present study [24] . These results show that Cur exerts its therapeutic effect on TNBSinduced colitis by decreasing the number of CD8 + CD11c + cells.
Previous research has shown that CD8 + DCs play an important role in the development of experimental colitis and human IBD [11, 12] . Our study showed that costimulatory molecules of DCs were increased in the spleen and PPs in untreated colitis mice, and Cur attenuated expression of MHC Ⅱ, CD205, CD40, CD40L and CD54 (ICAM1) in CD8 + DCs in the spleen and PPs. Our previous and present studies show that Cur can treat experimental colitis induced by TNBS or DSS [35, 36] . The present study proves that Cur regulates the levels of CD8 + DCs to treat TNBSinduced colitis.
DCs are essential in the activation of the adaptive immune system [37] , and can be distinguished into myeloid and lymphoid DCs based on the cellsurface expression of CD8 [8, 9] , which is one of the most important DC subset markers. Research has previously demonstrated that lymphoid DCs express CD8 in mice, whereas myeloid DCs do not [3840] . Thus, DCs in the spleen and PPs of mice are considered to be CD8 + DCs, which were identified in the present study [39, 41] . Overwhelming evidence suggests that activation of CD8 + DCs is a significant pathway to generate specific CD8 + Tcell immune responses [42, 43] . The complex pathway includes activation of Tolllike receptor 3 [44] , MHC and costimulatory molecule expression. MHC can promote DCs to migrate into lymphoid tissues such as the spleen and PPs, and accelerate antigen presentation, activation and maturation of DCs.
Researchers have previously incorporated MHC Ⅱ as a phenotypic segregation marker for ex vivo analysis of DCs under inflammatory settings such as influenza [44] . Waithman et al [45] + cells in colitis inflammatory zones [4648] . Based on the high expression of MHC Ⅱ, CD8 + DCs capture antigens and promote
Tcell migration at regions of the draining lymph nodes where they mature into functional DCs and present antigens to initiate primary immune responses [49, 50] . In the process of maturation and activation of CD8 + DCs, costimulatory molecules are highly expressed and include expression of CD205, CD24, CD40 and CD40L [2] . As a symbol of maturation and activation, DCs express costimulatory molecules including members of the tumor necrosis factor (TNF)/TNF receptor protein family, CD40/CD40L and OX40/OX40L, and members of the immunoglobulin superfamily including ICAM1/lymphocyte functionassociated antigen (LFA)1, and CD28/cytotoxic T lymphocyte associated antigen 4/B7. Collectively, these cellsurface expressed protein receptors and their cognate ligands regulate the balance between Th1 and Th2 responses, and were found to be highly expressed in human and animal colitis [51] . For example, CD40/CD40L signaling can stimulate DCs to secrete IL12, and direct the differentiation of CD4 + T cells into Th1 cells. Similar functions are present in the context of ICAM1/LFA1 signaling and the B71 molecular signaling pathway (i.e., the B7/CD28 signal) [52, 53] . More importantly, CD8 + DCs predominantly produce Th1promoting cytokines like IL12 p70 and IL12 p40, while CD8 + DCs lead to Th1 differentiation with reduced secretion of IFNγ and IL10 [8, 54, 55] , and enhanced secretion of the proinflammatory cytokine IL6, which is associated with autoimmunity and chronic inflammatory diseases [56] . These cytokines were previously shown to be closely related to the pathogenesis of IBD [57, 58] . 
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CD11c is a specific marker of dendritic cells (DCs) and is highly expressed in CD8 + and CD8 -DCs. Overaccumulation of CD8 + DCs is seen in colonic mucosa in experimental colitis and patients with inflammatory bowel disease (IBD).
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+ DCs predominantly stimulate T helper (Th)1-inducing cytokines like interleukin (IL)-12p70 and IL-12p40, which can lead to Th1 differentiation, and have been reported to play a key role in controlling viral infection. Overaccumulation of CD8 + DCs induces inflammatory injury in the colonic mucosa when they migrate into Peyer's patches in experimental colitis and in patients with IBD. Thus, CD8
+ DCs may be a potential therapeutic target to explore the mechanisms of clinical treatment of IBD.
Innovations and breakthroughs
The present study is believed to be the first to show that curcumin (Cur) can effectively treat experimental colitis, which was realized by inhibiting CD8 + CD11c + cells.
Applications
It is known that Cur has a long history of effectively treating human IBD and experimental colitis. Cur prevents DC-mediated induction of CD4 + T-cell proliferation by blocking expression of maturation markers, cytokines and chemokines. However, it is unclear whether Cur can regulate expression of CD8 + CD11c + cells to treat IBD. The present study suggests that Cur can treat experimental colitis, via inhibition of CD8 + CD11c + cells.
Terminology
CD11c is a type I transmembrane protein that mediates adherence between leukocytes and endothelial cells, and participates in exudation and phagocytosis of leukocytes.
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